Cannabinoid

Texas Original Announces Opening of Sugar Land Location, Launches New RSO Gummies

Retrieved on: 
Wednesday, March 27, 2024
Vitamins, Supplements, Tobacco, Cannabis, Alternative Medicine, General Health, Pharmaceutical, Health, Retail, Natural Resources, Oncology, Dark, Epilepsy, Spasticity, Cannabinoid, RSO, Patient, Flavonoid, Cancer, Terpene, Protein, Originality, THC, Physician, PTSD, Diabetic neuropathy, Medicinal plants

Texas Original , Texas’ leading medical cannabis provider, today announced the opening of its newest prescription pickup location in Sugar Land, Texas.

Key Points: 
  • Texas Original , Texas’ leading medical cannabis provider, today announced the opening of its newest prescription pickup location in Sugar Land, Texas.
  • Texas Original also announced the launch of its new Pineapple Gummies, a 20 mg THC-only product made with Rick Simpson Oil (RSO).
  • Alongside the company’s recently launched Dark Chocolate Bites and RSO Tincture, Texas Original’s Pineapple Gummies are among the first medical cannabis products in the state—and the first gummy product—to incorporate RSO.
  • Texans can obtain medical cannabis prescriptions through online clinics or local physicians registered with the Compassionate Use Registry of Texas.

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

Retrieved on: 
Tuesday, March 19, 2024
Biotechnology, Pharmaceutical, Other Manufacturing, Health, Mental Health, Chemicals, Plastics, Manufacturing, Other Health, Depression, Cannabinoid, Rheumatoid arthritis, Patient, Anxiety, IND, Addiction, Pathology, Therapy, Osteoarthritis, Arthropathy, Steroid, Pharmaceutical industry

The compounds are new chemical entities that include cannabinoids in conjugate form with COX-2 inhibitors and cannabinoids in conjugate form with selected steroids.

Key Points: 
  • The compounds are new chemical entities that include cannabinoids in conjugate form with COX-2 inhibitors and cannabinoids in conjugate form with selected steroids.
  • Royalty rates could range from 2.5% up to 10% on future sales, depending on meeting certain sales criteria.
  • Together, through the out-licensing of the two assets and meeting various development and sales milestones, Enveric could potentially receive milestone payments that total up to approximately $82 million.
  • “We look forward to working with our partner, and we are confident in their leadership and capabilities to continue the development of these compounds for both pharmaceutical and non-pharmaceutical applications to advance joint disease treatment options for patients.

Rare Cannabinoid Company Unveils 420 Deals on THC Mood Gummies & CBD Oils

Retrieved on: 
Friday, April 5, 2024
CBG, Cannabinoid, Hunger, Relaxation, CBC, Sleep, THCV, Cannabis, CBN, Happiness, Energy, Multimedia, THC

HONOLULU, April 4, 2024 /PRNewswire-PRWeb/ -- Rare Cannabinoid Company is thrilled to announce the early launch of their highly anticipated 420 deals! In celebration of this special occasion, they are offering cannabis and hemp enthusiasts the opportunity to stock up on their favorite products and have them delivered right to their doorsteps before April 20th.

Key Points: 
  • Offers include: Buy one get one half off THC Mood Gummies with Delta-9-THC for euphoric relaxation, CBC oil for mood improvement, and CBD oil for the entourage effect.
  • HONOLULU, April 4, 2024 /PRNewswire-PRWeb/ -- Rare Cannabinoid Company is thrilled to announce the early launch of their highly anticipated 420 deals !
  • By starting 420 sales early, customers can have their favorite CBD, THC, and rare cannabinoid oils and gummies arrive in time to celebrate cannabis and hemp wellness on April 20.
  • Rare Cannabinoid Company also offers customers the chance to try their THC and THC-free gummies for free!

Extract Labs Announces Launch of Organic, cGMP, Vegan Gummy Manufacturing for Wellness and Supplement Brands

Retrieved on: 
Thursday, April 4, 2024
CBD, Partnership, Safety, Kava, Life, Cannabinoid, CGMP, Organic, Fine chemical

Understanding the growing consumer demand for clean, ethical, and effective wellness products, Extract Labs' gummy manufacturing capabilities are set to redefine industry standards.

Key Points: 
  • Understanding the growing consumer demand for clean, ethical, and effective wellness products, Extract Labs' gummy manufacturing capabilities are set to redefine industry standards.
  • "Our mission at Extract Labs has always been to bring the purest, most innovative products to the market," said Craig Henderson, CEO of Extract Labs.
  • Brands looking to take advantage of Extract Labs' cutting-edge gummy manufacturing services are encouraged to reach out to explore how they can bring their product visions to life.
  • For more information on Extract Labs' gummy manufacturing services or to inquire about partnership opportunities, please contact:

Luxury Cannabis Boutique Dispensary High Seas Opens in Costa Mesa, Providing Shoppers With an Extraordinary Sensory Experience

Retrieved on: 
Monday, April 1, 2024
Cannabinoid, Taste, Harbor Boulevard, Perseverance, Coffee, Education, High Seas, Smell, Knowledge, History, Weeping Angel, Cannabis, System, Water, Music, San Francisco Chronicle, Los Angeles Times, Hearing, Drug

COSTA MESA, Calif., April 1, 2024 /PRNewswire/ -- High Seas, a premier cannabis boutique located at 1921 Harbor Blvd in Costa Mesa, is thrilled to announce its grand opening today. The concept boutique offers an upscale shopping experience that seeks to remove barriers for Southern California cannabis shoppers—lack of knowledge, intimidation, or murky language—that prevent them from enjoying cannabis to enrich and achieve their lifestyle and wellness goals.

Key Points: 
  • Upon entering the Orange County cannabis boutique, shoppers will be transported on a sensory journey that engages touch, taste, sight, hearing, and smell.
  • A virtual staff member welcomes and invites you to explore the boutique, starting with a showcase of several cannabis brands.
  • Michael Moussalli, co-founder of High Seas, said, "Many shoppers in the Orange County and Costa Mesa communities are curious about the wellness and lifestyle benefits of cannabis.
  • Rachel Xin, co-founder of High Seas, added, "The entire boutique is designed to welcome guests by engaging their senses and their imaginations.

StickIt Technologies Announces Major Breakthrough in Cannabinoid Technology

Retrieved on: 
Monday, March 25, 2024
Cannabis, Cannabinoid, Taste, TEL, Today, Smoke

TEL AVIV, Israel, March 25, 2024 /PRNewswire/ -- StickIt Technologies Inc. (the "Company" or "StickIt") (CSE: STKT), an Israeli technology and cannabinoid company, today revealed that StickIt has initiated a substantial leap forward in the consumption methods of cannabinoids.

Key Points: 
  • TEL AVIV, Israel, March 25, 2024 /PRNewswire/ -- StickIt Technologies Inc. (the "Company" or "StickIt") (CSE: STKT), an Israeli technology and cannabinoid company, today revealed that StickIt has initiated a substantial leap forward in the consumption methods of cannabinoids.
  • Eli Ben Haroosh, CEO, commented, "Today marks a monumental day for StickIt Technologies Inc. as we unveil a groundbreaking advancement in cannabinoid consumption.
  • And right here in Calgary, Alberta, my R&D team is transforming the future with a remarkable advance in cannabinoid technology.
  • Cannabinoid producers now have the opportunity to tap into a new, lucrative revenue channel using the StickIt solid-phase technology and mass production systems.

ElleVet Sciences Announces Expansion of Executive Leadership Team

Retrieved on: 
Tuesday, March 19, 2024
Consumer, Certified Public Accountant, Health, Certification, Machine learning, Cannabinoid, Growth, Shadrin, Science, Husson University, CBD, MBA, CBDA, Hamilton College, Safety, Operation, Pet, Multimedia, Marketing, Management

SOUTH PORTLAND, Maine, March 19, 2024 /PRNewswire-PRWeb/ -- ElleVet Sciences, the first company to prove the safety and efficacy of its hemp-based CBD products for pets, announces the recent expansion of its executive leadership team with the promotion of Haley Israelson to Chief Financial Officer, and addition of Ryan Shadrin as Chief Commercial Officer.

Key Points: 
  • SOUTH PORTLAND, Maine, March 19, 2024 /PRNewswire-PRWeb/ -- ElleVet Sciences , the first company to prove the safety and efficacy of its hemp-based CBD products for pets, announces the recent expansion of its executive leadership team with the promotion of Haley Israelson to Chief Financial Officer, and addition of Ryan Shadrin as Chief Commercial Officer.
  • "My journey with ElleVet has been one of personal and professional growth, and I'm excited to continue driving innovation and creating significant value with the ElleVet team."
  • The expansion of the ElleVet leadership team is a key milestone in the company's strategic growth plan.
  • "We are excited to announce the promotion of Haley and the hiring of Ryan as we continue to grow ElleVet Sciences and explore the role of cannabinoids in animal health," said Christian Kjaer, CEO and Co Founder of ElleVet Sciences.

Charlotte's Web Launches" Stay Asleep" CBN Gummies

Retrieved on: 
Tuesday, March 19, 2024
Cannabinoid, Entrepreneurship, Science, Sleep, GMO, Charlotte's Web, News, CBD, CWEB, Stay Asleep, TSX, CBN, Web, Cannabinol, Pharmaceutical industry

LOUISVILLE, Colo., March 19, 2024 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the leading provider of hemp-derived CBD wellness products, has formally launched its latest innovation, "Stay Asleep" CBN Gummies.

Key Points: 
  • LOUISVILLE, Colo., March 19, 2024 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the leading provider of hemp-derived CBD wellness products, has formally launched its latest innovation, "Stay Asleep" CBN Gummies.
  • The launch of Charlotte's Web Stay Asleep CBN Gummies is a testament to this commitment.
  • Developed under the leadership of Charlotte's Web's Chief Scientific Officer, Dr. Marcel Bonn-Miller, the Stay Asleep CBN Gummies demonstrate Charlotte's Web commitment to science-backed products, providing an effective alternative to more traditional sleep supplements and medications.
  • With millions of Americans grappling with sleep issues1, the Stay Asleep CBN Gummies embody Charlotte's Web's mission to unearth the science of nature to revolutionize wellness.

Gynica announces First-in-Human Clinical Trial of Novel IntraVag© Treatment for Endometriosis

Retrieved on: 
Thursday, March 14, 2024
Health, Cannabinoid, Uterus, Conditional sentence, Prevalence, Patient, EMA, ECS, Quality of life, Society, Trial of the century, European Medicines Agency, Woman, API, Safety, Pharmacokinetics, FDA, Food

FLORENCE, Italy, March 14, 2024 /PRNewswire/ -- Gynica, a clinical-stage women's health biotech startup developing a novel Endometriosis treatment, announces today the submission of a first-in-human Phase 1 trial. The global first-of-its-kind clinical study will take place at Careggi University Hospital in Florence, Italy. It will evaluate the safety, tolerability, and pharmacokinetics of the IntraVag© intra-vaginal drug delivery platform and two proprietary drug candidates, S-301 and S-302. 

Key Points: 
  • The physical and emotional tolls are immense, disrupting careers, relationships, and overall quality of life for these women.
  • The trial will be led by world-renowned Endometriosis expert Prof. Felice Petraglia, Past President and founding member of the Society for Endometriosis and Uterine Disorders (SEUD).
  • Gynica aims to pursue registration of its novel solutions with the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
  • In this enormous unmet need, patients urgently seek efficient solutions," stated Yotam Hod, CEO of Gynica.

Gynica announces First-in-Human Clinical Trial of Novel IntraVag© Treatment for Endometriosis

Retrieved on: 
Thursday, March 14, 2024
Health, Cannabinoid, Uterus, Conditional sentence, Prevalence, Patient, EMA, ECS, Quality of life, Society, Trial of the century, European Medicines Agency, Woman, API, Safety, Pharmacokinetics, FDA, Food

FLORENCE, Italy, March 14, 2024 /PRNewswire/ -- Gynica, a clinical-stage women's health biotech startup developing a novel Endometriosis treatment, announces today the submission of a first-in-human Phase 1 trial. The global first-of-its-kind clinical study will take place at Careggi University Hospital in Florence, Italy. It will evaluate the safety, tolerability, and pharmacokinetics of the IntraVag© intra-vaginal drug delivery platform and two proprietary drug candidates, S-301 and S-302. 

Key Points: 
  • The physical and emotional tolls are immense, disrupting careers, relationships, and overall quality of life for these women.
  • The trial will be led by world-renowned Endometriosis expert Prof. Felice Petraglia, Past President and founding member of the Society for Endometriosis and Uterine Disorders (SEUD).
  • Gynica aims to pursue registration of its novel solutions with the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
  • In this enormous unmet need, patients urgently seek efficient solutions," stated Yotam Hod, CEO of Gynica.